Kathy L. McGraw

3.5k citations

53 papers · 1.2k indexed · h-index 18

Co-authors: Alan F. List Rami S. Komrokji David A. Sallman Eric Padron Lubomir Sokol Joseph Johnson Jeffrey E. Lancet Ashley A. Basiorka
Topics: Acute Myeloid Leukemia Research (27 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers)Inflammasome and immune disorders (8 papers)
Cited by: Hematology Genetics Immunology
Journals: Journal of Clinical Oncology Blood PLoS ONE
Partner nations: United States France Taiwan

In The Last Decade

Kathy L. McGraw

50 papers receiving 1.2k citations

Peers

Countries citing papers authored by Kathy L. McGraw

Since Specialization

Citations

This map shows the geographic impact of Kathy L. McGraw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy L. McGraw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy L. McGraw more than expected).

Fields of papers citing papers by Kathy L. McGraw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathy L. McGraw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy L. McGraw. The network helps show where Kathy L. McGraw may publish in the future.

Co-authorship network of co-authors of Kathy L. McGraw

This figure shows the co-authorship network connecting the top 25 collaborators of Kathy L. McGraw. A scholar is included among the top collaborators of Kathy L. McGraw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathy L. McGraw. Kathy L. McGraw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implications for metabolic disturbances in myelodysplastic syndromes 2024 ·Seminars in Hematology ·Kathy L. McGraw,Daniel R. Larson	1
2	Predicted leukocyte telomere length and risk of myeloid neoplasms 2023 ·Human Molecular Genetics ·Shannon M. Sullivan,Ben Cole,John Lane,(unknown),Erica Langer,Anthony J. Hooten,Michelle A. Roesler,Kathy L. McGraw,Nathan Pankratz,Jenny N. Poynter	4
3	Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes 2022 ·JCI Insight ·Amy F. McLemore,Hsin‐An Hou,(unknown),(unknown),Grace Ward,Amy L. Aldrich,Matthew A. Rodrigues,Alexis Vedder,Ling Zhang,Eric Padron,Nicole D. Vincelette,David A. Sallman,Omar Abdel‐Wahab,Alan F. List,Kathy L. McGraw	26
4	The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms 2022 ·Blood ·(unknown),(unknown),Maria E. Balasis,(unknown),Traci Kruer,Lei Sun,Christopher T. Letson,(unknown),Chetasi Talati,Meghan C. Ferrall‐Fairbanks,Alexis Vedder,Kathy L. McGraw,Rami S. Komrokji,Ma Li,Eric Padron	1
5	Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin 2021 ·Haematologica ·Chen Wang,Kathy L. McGraw,Amy F. McLemore,Rami S. Komrokji,Ashley A. Basiorka,Najla Al Ali,Jeffrey E. Lancet,Eric Padron,Olivier Kosmider,Michaëla Fontenay,Pierre Fenaux,Alan F. List,David A. Sallman	3
6	Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks 2019 ·Clinical Cancer Research ·(unknown),Wen-Liang Kuo,(unknown),Gaurav S. Choudhary,Shanisha Gordon-Mitchell,Hui Liu,Tushar D. Bhagat,Kathy L. McGraw,Sandeep Gurbuxani,Alan F. List,Amit Verma,Amittha Wickrema	9
7	A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) 2019 ·Leukemia Research ·David A. Sallman,Rami S. Komrokji,Kendra Sweet,Qianxing Mo,Kathy L. McGraw,Vu H. Duong,Ling Zhang,Lisa Nardelli,Eric Padron,Alan F. List,Jeffrey E. Lancet	24
8	Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes 2018 ·Blood ·Grace Ward,Kathy L. McGraw,Amy F. McLemore,Farnoosh Abbas‐Aghababazadeh,Hsin‐An Hou,Thu Le Trinh,Nicole D. Vincelette,(unknown),(unknown),(unknown),Erika A. Eksioglu,Sheng Wei,Alan F. List	1
9	Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype 2017 ·Blood ·David A. Sallman,(unknown),Rami S. Komrokji,Kathy L. McGraw,Susan Geyer,Erika A. Eksioglu,Najla Al Ali,Jeffrey E. Lancet,Sheng Wei,Eric Padron,Alan F. List	6
10	The S100A9/Fto Axis Induces Formation of RNA:DNA Hybrids That Serve As Damps Initiating Myeloid Skewing & Genetic Injury in MDS 2017 ·Blood ·Erika A. Eksioglu,Xianghong Chen,Pingyan Cheng,Jinhong Liu,Kathy L. McGraw,David A. Sallman,Eric Padron,Alan F. List,Sheng Wei	0
11	Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes 2017 ·Haematologica ·Thomas Cluzeau,Kathy L. McGraw,Brittany Irvine,Erico Masala,Lionel Adès,Ashley A. Basiorka,Jaroslaw P. Maciejewski,Patrick Auberger,Sheng Wei,Pierre Fenaux,Valeria Santini,Alan F. List	32
12	Erythropoietin Receptor Signaling and Lipid Rafts 2017 ·Vitamins and hormones ·Kathy L. McGraw,Alan F. List	9
13	Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858 2017 ·Leukemia ·Erika A. Eksioglu,X Chen,K-H Heider,(unknown),Kathy L. McGraw,Ashley A. Basiorka,(unknown),(unknown),Pingyan Cheng,Jeffrey E. Lancet,Rami S. Komrokji,J Y Djeu,Alan F. List,Sheng Wei	53
14	Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes 2015 ·Leukemia ·David A. Sallman,Rami S. Komrokji,Christine Vaupel,Thomas Cluzeau,Susan Geyer,Kathy L. McGraw,Najla H. Al Ali,Jeffrey E. Lancet,Matthew J. McGinniss,Shareef Nahas,Alexander Smith,Austin Kulasekararaj,G J Mufti,Alan F. List,Jeff Hall,Eric Padron	137
15	30 MDS GENETIC DAMAGE IS LINKED TO INFLAMMAGING INDUCED BONE MARROW HYPERGLYCEMIA 2015 ·Leukemia Research ·Wei Shi,Erika A. Eksioglu,Thomas Cluzeau,(unknown),Ashley A. Basiorka,(unknown),(unknown),Kathy L. McGraw,Eric Padron,Alan F. List	1
16	Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors 2014 ·PLoS ONE ·Kathy L. McGraw,Ashley A. Basiorka,Joseph Johnson,Justine Clark,Gisela Cáceres,Eric Padron,Ruth Heaton,Yukiyasu Ozawa,Sheng Wei,Lubomir Sokol,Alan F. List	21
17	Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide 2012 ·Journal of Hematology & Oncology ·Yuka Sugimoto,Mikkael A. Sekeres,Hideki Makishima,Fabı́ola Traina,Valeria Visconte,Anna Jankowska,Andrés Jerez,Hadrian Szpurka,Christine L. O’Keefe,Kathryn M Guinta,Manuel Afable,Ramón V. Tiu,Kathy L. McGraw,Alan F. List,Jaroslaw P. Maciejewski	18
18	Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion 2012 ·Oncogene ·Sheng Wei,X Chen,Kathy L. McGraw,(unknown),Rami S. Komrokji,Justine Clark,Gisela Cáceres,(unknown),Lubomir Sokol,Jeffrey E. Lancet,Nicole Fortenbery,Jianwei Zhou,Erika A. Eksioglu,David A. Sallman,(unknown),Pearlie K. Epling‐Burnette,J Y Djeu,Mikkael A. Sekeres,Jaroslaw P. Maciejewski,Alan F. List	74
19	Erythropoietin Receptor Signaling Is Membrane Raft Dependent 2012 ·PLoS ONE ·Kathy L. McGraw,Gwenny M. Fuhler,Joseph Johnson,Justine Clark,(unknown),Lubomir Sokol,Alan F. List	26
20	Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes 2011 ·British Journal of Haematology ·Lubomir Sokol,Gisela Cáceres,Stefano Volinia,(unknown),Gerard J. Nuovo,Chang‐Gong Liu,Kathy L. McGraw,Justine Clark,Celia Sigua,Dung‐Tsa Chen,Lynn C. Moscinski,Carlo M. Croce,Alan F. List	59

About Kathy L. McGraw

Kathy L. McGraw is a scholar working on Hematology, Genetics and Immunology, having authored 53 papers that have together received 1.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Inflammasome and immune disorders (8 papers). The work is most often cited by research in Hematology (756 citations), Genetics (343 citations) and Immunology (308 citations). Kathy L. McGraw has collaborated with scholars based in United States, France and Taiwan. Frequent co-authors include Alan F. List, Rami S. Komrokji, David A. Sallman, Eric Padron, Lubomir Sokol, Joseph Johnson, Jeffrey E. Lancet, Ashley A. Basiorka, Thomas Cluzeau and Erika A. Eksioglu. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact